Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma
Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma
RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness
 caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade
 glioma.

 PURPOSE: This randomized clinical trial is studying how well testosterone gel works in
 preventing weakness caused by steroid therapy in men receiving glucocorticoids for newly
 diagnosed high-grade glioma.
OBJECTIVES:

 Primary

 -  To determine if daily administration of testosterone gel can prevent the development or
 reduce the severity of muscle weakness in men receiving glucocorticoids for newly
 diagnosed high-grade glioma.

 Secondary

 -  To compare the difference in percent change from baseline timed functional tests (TFT)
 between patients who are treated with testosterone gel and those who are not.

 -  To compare the difference in percent change from baseline activities of daily living as
 assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) between
 patients who are treated with testosterone gel and those who are not.

 -  To compare the difference in percent change from baseline leg muscle mass as assessed by
 CT scan imaging between patients who are treated with testosterone gel and those who are
 not.

 -  To estimate the side effects of testosterone gel in these patients.

 OUTLINE: Patients are stratified according to daily glucocorticoid dose (< 16 mg/day vs ≥ 16
 mg/day), Karnofsky performance status (≤ 80% vs > 80%), and age (≤ 50 years of age vs > 50
 years of age). Patients are randomized to 1 of 2 treatment arms.

 -  Arm I (control): Patients receive oral whey protein powder once daily for 7 months.

 -  Arm II (treatment): Patients apply topical testosterone gel to the shoulder, upper
 chest, or forearm once daily for 7 months.

 Patients undergo strength testing and functional testing (TFT) and complete an activities of
 daily living questionnaire at baseline and at 1, 3, 5, and 7 months. Patients also undergo CT
 scan of the leg and laboratory testing at baseline and at 3 and 7 months. Testosterone levels
 are obtained at baseline and at 1, 3, and 7 months.

 Patients complete a daily log of their glucocorticoid dose and to affirm compliance with
 therapy. Major clinical events related to underlying tumor (i.e., surgery, radiotherapy,
 initiating chemotherapy, concurrent antiepileptic therapy, deep vein thrombosis, pulmonary
 embolism, transfusions, seizures, pneumonia, and other forms of infection) are also recorded.
DISEASE CHARACTERISTICS:

 -  Newly diagnosed high-grade glioma, including the following subtypes:

 -  Anaplastic astrocytoma

 -  Anaplastic oligodendroglioma

 -  Glioblastoma multiforme

 -  Requires dexamethasone at a dose of > 4 mg/day to control symptoms of tumor-related
 edema at time of study enrollment AND has been on a stable dose of steroids for ≥ 5
 days prior to study enrollment

 -  Completed ≥ 80% of prescribed radiotherapy

 -  Hypogonadal, defined as serum testosterone level < 350 ng/dL

 -  No history of prostate or breast cancer

 -  No benign prostatic hypertrophy requiring therapy OR AUA score of ≥ 8

 -  PSA ≤ 4 ng/mL

 PATIENT CHARACTERISTICS:

 -  Karnofsky performance status 60-100%

 -  Able to keep daily records or has a care provider that agrees to keep daily records of
 drug administration

 -  No clinical history of congestive heart failure requiring therapy

 -  No psychotic disorder requiring active treatment

 -  No structured exercise program involving exercise for > 3 hours/week

 -  No polycythemia (i.e., hematocrit > 52%)

 PRIOR CONCURRENT THERAPY:

 -  More than 6 months since prior androgen therapy